Carrageenan-Induced Chronic Thrombosis Model

Model Description

Carrageenan, a sulfated polysaccharide derived from red algae, is a gold-standard inducer for chronic thrombosis research. Our mouse tail thrombosis model leverages carrageenan’s unique properties to achieve:

• Controlled thrombogenesis: Progressive fibrin deposition over 6-10 days
• Non-invasive monitoring: Visible tail darkening (≥2mm "black tail" length as endpoint)
• High translational relevance: Mimics human venous thromboembolism (VTE) pathophysiology

Key Advantages:
✓ Cost-effective scalability: 90% success rate with minimal equipment
✓ Gradual progression: Ideal for testing prophylactic therapies
✓ Dual readouts: Thrombus length quantification + coagulation profiling

Applications

• Anticoagulant/antiplatelet drug screening (DOACs, heparin analogs)
• Natural therapy evaluation (acupuncture, moxibustion mechanisms)
• Thrombosis prevention strategy development
• Coagulation cascade pathway studies

Modeling Protocol —— 6-Day Carrageenan Induction

1. Group Design: 

• Control Group: Daily intraperitoneal (i.p.) saline (0.01 mL/g)
• Model Group: Daily i.p. 0.06% carrageenan (0.01 mL/g)

2. Procedure:

Days 1-6: Inject carrageenan at 20±1°C ambient temperature

Terminal Criteria:

（1）Immediate sacrifice upon black tail appearance (thrombus formation)

（2）Continue injections until Day 10 for non-responders

Validation & Testing

Technical Advantages